GlassScriptPhysician profile
Catherine Cannan
NPI 1740821115
$3,565.36
in general payments reported to CMS, 2019-2025
22 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $996 · 2023: $720 · 2024: $196 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Consulting Fee: $115 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.53 |
| Consulting Fee | $115.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $527.47 | 2022-2025 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $508.78 | 2021-2024 | Darzalex, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $410.02 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| Beigene USA, INC. | $233.26 | 2021 | |
| Abbvie INC. | $228.85 | 2021-2025 | |
| Incyte Corporation | $185.95 | 2022-2025 | Jakafi, Zynyz |
| Genentech USA, INC. | $176.00 | 2022-2025 | Lunsumio, Tecentriq |
| Celgene Corporation | $173.83 | 2022-2025 | Reblozyl, Opdualag, Opdivo |
| Medtronic, INC. | $134.68 | 2025 | Synchromedii |
| Glaxosmithkline, LLC. | $124.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.80 | 2022 | |
| Servier Pharmaceuticals LLC | $124.80 | 2023 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Talvey |
| Array Biopharma INC | $109.68 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Genzyme Corporation | $99.43 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $74.43 | 2024 | |
| Daiichi Sankyo INC. | $72.46 | 2023-2025 | Injectafer, Vanflyta, Datroway |
| Pfizer INC. | $61.77 | 2025 | |
| Coherus Oncology, INC. | $22.41 | 2025 | Loqtorzi |
| Lundbeck LLC | $21.23 | 2025 | Vyepti |
| Epizyme, INC. | $19.41 | 2021 | |
| Merck Sharp & Dohme LLC | $16.11 | 2025 | Keytruda, Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Cannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.